Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial.

MLA

Brugières, Laurence, et al. “Efficacy and Safety of Crizotinib in ALK-Positive Systemic Anaplastic Large-Cell Lymphoma in Children, Adolescents, and Adult Patients: Results of the French AcSé-Crizotinib Trial.” European Journal of Cancer (Oxford, England : 1990), vol. 191, Sept. 2023, p. 112984. EBSCOhost, https://doi.org/10.1016/j.ejca.2023.112984.

APA

Brugières, L., Cozic, N., Houot, R., Rigaud, C., Sibon, D., Arfi-Rouche, J., Bories, P., Cottereau, A. S., Delmer, A., Ducassou, S., Garnier, N., Lamant, L., Leruste, A., Millot, F., Moalla, S., Morschhauser, F., Nolla, M., Pagnier, A., Reguerre, Y., … Vassal, G. (2023). Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial. European Journal of Cancer (Oxford, England : 1990), 191, 112984. https://doi.org/10.1016/j.ejca.2023.112984

Chicago

Brugières, Laurence, Nathalie Cozic, Roch Houot, Charlotte Rigaud, David Sibon, Julia Arfi-Rouche, Pierre Bories, et al. 2023. “Efficacy and Safety of Crizotinib in ALK-Positive Systemic Anaplastic Large-Cell Lymphoma in Children, Adolescents, and Adult Patients: Results of the French AcSé-Crizotinib Trial.” European Journal of Cancer (Oxford, England : 1990) 191 (September): 112984. doi:10.1016/j.ejca.2023.112984.